REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026TRENDINGHexarelin: ↑↑ Surging ��� Trends score 100 as of May 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingEVENTpep-talk con ��� First US Peptide Convention · August 2026 · Anaheim CAFDAFDA advisory committee meetings scheduled: late July 2026

For research purposes only. Full disclaimer →

Stack Library

Natural GH Pulse

GH Optimizationbeginner

90

synergy

90
Peptides

2

Avg Daily mcg

300

Level

beginner

Added

May 17, 2026

Overview

The Natural GH Pulse stack combines a growth hormone releasing hormone (GHRH) analog with a selective growth hormone secretagogue to produce amplified, pulsatile GH release that mimics the body''s natural rhythm. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) is a truncated and modified analog of endogenous GHRH that stimulates the pituitary to produce growth hormone. Its short half-life (approximately 30 minutes) means it generates discrete GH pulses rather than sustained elevation, preserving the body''s natural feedback mechanisms. Ipamorelin is a pentapeptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, triggering GH release without significantly affecting cortisol, prolactin, or ACTH levels — making it the cleanest growth hormone secretagogue available. Unlike older secretagogues such as GHRP-6, Ipamorelin does not stimulate appetite or raise cortisol, making it suitable for long-term use. The synergy between CJC-1295 (no DAC) and Ipamorelin is well-documented: GHRH analogs and ghrelin-mimetics act through different receptors on the same pituitary cells, producing an amplified GH pulse approximately 3-5x greater than either peptide alone. This phenomenon is called the "GH synergy effect" and has been demonstrated in human clinical studies. The combined pulse mimics the magnitude of youthful GH secretion while maintaining pulsatility, which is critical for avoiding GH receptor desensitization. Benefits include improved sleep architecture (deeper slow-wave sleep), enhanced recovery from exercise, modest fat reduction, and improved skin quality over 3-6 months of consistent use.

Dosing Protocol

CJC-1295 (no DAC)

Every day· subcutaneous

100 mcg

per dose

Ipamorelin

Every day· subcutaneous

200 mcg

per dose

Goals & Evidence

Growth hormoneAnti-agingFat lossSleep qualityRecovery
Evidence tier:Human RCT

Warnings

  • CJC-1295 and Ipamorelin are both FDA Category 2 pending reclassification. Do not use with active cancer.

Disclaimer: This stack is community-submitted and for research purposes only. PeptideVault does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.